Merck Receives Approval of ZEPATIER™

CNW Group 2016-02-03

Views 7

Merck Receives Approval of ZEPATIER™ (elbasvir/grazoprevir) in Canada for the Treatment of Chronic Hepatitis C for Patients with Genotype 1, 3, or 4 Infection Following Priority Review - http://dld.bz/em2kD

Share This Video


Download

  
Report form